Product Description
PCA062 is a P-cadherin specific antibody-drug conjugate that utilizes the clinically validated SMCC-DM1 linker payload to mediate potent cytotoxicity in cell lines expressing high levels of P-cadherin in vitro, while displaying no specific activity in P-cadherin-negative cell lines. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33879555/)
Mechanisms of Action: P-Cadherin Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Esophageal Cancer|Triple Negative Breast Cancer|Head and Neck Cancer|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-152921 |
JapicCTI-152921 | P1 |
Terminated |
Oncology Unspecified |
2018-12-01 |
|||
NCT02375958 |
CPCA062X2101 | P1 |
Completed |
Triple Negative Breast Cancer|Esophageal Cancer|Head and Neck Cancer |
2018-07-17 |
2019-06-25 |
Treatments |